GeneOne Life Science Subsidiary VGXI Transfers Texas Plant Ownership as Collateral for Debt Extension, No Share Dilution

GeneOne Life Science responded to a inquiry regarding its subsidiary VGXI Inc.'s deed in lieu of foreclosure with lease and buyback option agreement with C2R Secured Funding LLC.
The agreement transfers legal ownership of the Texas plant to C2R Secured Debt Fund I LP, but the substance is a collateralized mortgage loan to extend existing debt, not a true sale under GAAP and IFRS.
VGXI retains a buyback option and continues to bear control and substantial risks of the asset, so the plant remains on its books as property, plant, and equipment. No new shares were issued and no equity dilution occurred.
Additional disclosure is expected by September 1, 2026, the loan maturity date. While default could lead to loss of ownership, the transaction is defensive capital allocation aimed at avoiding immediate financial distress.
[AI Summary]This transaction by GeneOne Life Science is a defensive measure to extend debt without diluting shareholder value. The counterparty is an unlisted private fund with low transparency, and there is risk of losing the plant in case of default, but the move provides near-term financial stability, resulting in a neutral impact on shareholder value.